ClinicalTrials.gg
TerminatedNCT01539291Updated Aug 20, 2019Results posted

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

A Phase 3 interventional study of Idelalisib in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 45 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
9th of 25
161 · median 102
Started
2012
with 4 others
Phase 3
8 of 25
none open now
Registered
6th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and carried forward to study GS-US-312-117.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
  • CAL-101
  • CAL 101
  • GS-1101
  • GS 1101
  • PI3K
  • Leukemia
  • GS-US-312-0116
  • idelalisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals in the primary Phase 3 study (Study GS-US-312-0116) who are compliant
  • Tolerating primary study therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    High-dose Idelalisib

    Participants will receive idelalisib 300 mg twice daily (600 mg per day).

    Drug: Idelalisib

  • Experimental
    Standard-dose Idelalisib

    Participants will receive idelalisib 150 mg twice daily (300 mg per day)

    Drug: Idelalisib

Interventions

  • Idelalisib tablet(s) administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL 101

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the interval from the start of study therapy to the earlier of the first documentation of definitive disease progression or death from any cause; definitive disease progression is chronic lymphocytic leukemia (CLL) progression based on standard criteria other than lymphocytosis alone. PFS was analyzed using Kaplan-Meier (KM) estimates.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  2. Safety: Percentage of Participants With Any Treatment-Emergent Adverse Events (TEAE), ≥ Grade 3 TEAE, Study Drug-Related TEAE, ≥ Grade 3 Study Drug-Related TEAE, Serious TEAE, Study Drug-Related Serious TEAE, and TEAE Leading to Study Drug Discontinuation

    The TEAEs were defined as events in a given study period that met one of the following criteria: * Events with onset dates on or after the start of treatment and up to 30 days after the permanent discontinuation of the study treatment. * The continuing adverse events (AEs) diagnosed prior to the start of treatment and worsened in severity grade, or non-serious AEs at baseline which became serious, or AEs resulting in treatment discontinuation after the start of treatment. The severity of AEs was graded by the investigator according to the common terminology criteria for adverse events (CTCAE), Version 4.03, whenever possible. The relationship of an AE to study drug (idelalisib) was assessed using clinical judgment by the investigator, describing the event as either unrelated or related. Events for which the investigator did not record relationship to study drug were considered related to study drug.

    Time frame: First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months) plus 4 weeks

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). The determination of CLL response and progression were based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs. CR and PR are defined in Protocol Amendment 9, Sections 7.5.1 and 7.5.2.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  2. Lymph Node Response Rate

    Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  3. Complete Response (CR) Rate

    CR rate was defined as the percentage of participants who achieved a CR (full definition in Protocol Amendment 9, Section 7.5.1). The determination of CLL response and progression were based on standardized IWCLL criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  4. Time to Response (TTR)

    TTR was defined as the time interval from start of study therapy to the first documentation of CR or PR.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  5. Duration of Response (DOR)

    DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause. DOR was analyzed using KM estimates.

    Time frame: From first documentation of CR or PR to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  6. Best Percent Change in Lymph Node Area

    The best percent change from baseline in lymph node area (SPD) was defined as the largest decrease in tumor size during the study. The baseline SPD was the last value prior to the baseline reference date. For the participants who only had increases in tumor size from baseline, the smallest increase was considered as the best change from baseline in SPD.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  7. Splenomegaly Response Rate

    Splenomegaly response rate was defined as the percentage of participants with baseline splenomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the enlargement of the splenic longest vertical dimension (LVD) (by imaging).

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  8. Hepatomegaly Response Rate

    Hepatomegaly response rate was defined as the percentage of participants with baseline hepatomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the hepatic LVD (by imaging).

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  9. Absolute Lymphocyte Count (ALC) Response Rate

    ALC response rate was defined as the percentage of participants with baseline lymphocytosis (ALC ≥ 4 x 10\^9 cells/L) who achieved an on-study ALC \< 4 x 10\^9 cells/L or demonstrated a ≥ 50% decrease in ALC from baseline; ALC values within 4 weeks post-baseline were excluded from the ALC response rate evaluation.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  10. Platelet Response Rate

    Platelet response rate was defined as the percentage of participants with baseline thrombocytopenia (platelet count \< 100 x 10\^9/L) who achieved an on-study platelet count ≥ 100 x 10\^9/L or demonstrated a ≥ 50% increase in platelet count from baseline; platelet values within 4 weeks post-baseline or after 8 days post transfusion were excluded from the platelet response rate evaluation.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  11. Hemoglobin Response Rate

    Hemoglobin response rate was defined as the percentage of participants with baseline anemia (hemoglobin \< 110 g/L \[11.0 g/dL\]) who achieved an on-study hemoglobin ≥ 110 g/L (11.0 g/dL) or demonstrated a ≥ 50% increase in hemoglobin from baseline; hemoglobin values within 4 weeks post-baseline or after 4 weeks of receiving packed cell/whole blood transfusion or after 6 weeks of receiving exogenous growth factors (eg, darbepoetin alfa) were excluded from the hemoglobin response evaluation.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  12. Neutrophil Response Rate

    Neutrophil response rate was defined as the percentage of participants with baseline neutropenia (absolute neutrophil count \[ANC\] ≤ 1.5 x 10\^9/L) who achieved an ANC \> 1.5 x 10\^9/L or demonstrated a ≥ 50% increase in ANC from baseline; ANC values within 4 weeks of post-baseline or after 2 weeks of receiving exogenous growth factors (eg, filgrastim, granulocyte-colony stimulating factor \[G-CSF\], lenograstim) or after 4 weeks of receiving Neulasta® were excluded from response evaluation.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  13. Overall Survival

    Overall survival was defined as the time interval from start of study therapy to death from any cause. Overall survival was analyzed using KM estimates. Data presented includes all available survival information from Study GS-US-312-0116 (including data in long-term follow-up) and Study GS-US-312-0117 (including any data in long-term follow-up) up to the database finalization dates. Data from surviving participants were censored at the last time that the participant was known to be alive on study or long-term follow-up. Data presented includes all participants who were randomized to Study GS-US-312-0116 regardless if they entered Study GS-US-312-0117 or not.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  14. Best Change From Baseline in Health-Related Quality of Life (HRQL) Domain and Symptom Scores Based on the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire

    The FACT-Leu questionnaire included subscales for physical well-being (PWB, 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB, 6 items), functional well-being (FWB, 7 items), and additional concerns or Leukemia-Specific Subscale (LeuS, 17 items). The FACT-Leu scoring guide identified those negatively stated items that must have been reversed before being added to obtain subscale totals. Negatively stated items were reversed by subtracting the response from "4". After reversing proper items, all subscale items were summed to get total subscale scores with the range of 0-28, 0-28, 0-24, 0-28, 0-68 for PWB, SWB, EWB, FWB, and LeuS, respectively. FACT-Leu total score ranged from 0 to 176. Higher scores indicated a better quality of life. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.

    Time frame: Study GS-US-312-0116 or GS-US-312-0117 Baseline up to Week 184

  15. Best Change From Baseline in Karnofsky Performance Status (KPS)

    KPS is a tool used to measure the ability to perform ordinary tasks. The score ranges from 0 to 100, with a higher score indicating that the participant is better able to carry out daily activities. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.

    Time frame: Study GS-US-312-0116 or GS-US-312-0117 Baseline up to Week 190

  16. Changes From Baseline in Phosphatidylinositol 3-kinase (PI3Kδ)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway Activation as a Measure of PI3Kδ Pathway Activity

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  17. Overall Change From Baseline in the Plasma Concentrations of Disease-Associated Chemokines and Cytokines

    The percent of average on-treatment biomarker concentration of baseline (%Baseline) was used to evaluate the overall pharmacodynamics change on the biomarkers with IDL treatment. The average on-treatment biomarker concentration is calculated using area under curve (AUC) following the trapezoidal rule. The biomarkers with median AUC value of 100 indicated no overall on-treatment biomarker changes compared to the baseline. The biomarkers with median AUC value greater than 100 or less than 100 indicated an increase or decrease, respectively, on-treatment biomarker changes from the baseline.

    Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

  18. Study Drug Compliance as Assessed by the Percentage of Participants Adhering to Treatment

    Adherence percentage was calculated as the sum of tablets dispensed - the sum of tablets returned divided by the sum of the overall dosing period (total daily tablets x dosing duration), taking into account investigator-prescribed interruptions.

    Time frame: First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months)

  19. Plasma Trough (Predose) and Peak (1.5 Hours Postdose) Concentrations of Idelalisib

    Time frame: Weeks 4, 12, and 24

  20. Change in Health Status as Assessed Using the EuroQoL Five-Dimension (EQ-5D) Utility Measure

    Change in health status was defined as the change from baseline in overall health and single-item dimension scores as assessed using the EQ-5D utility measure. Percentage of participants with different level of problem were reported. Level 1: indicated no problem; Level 2: indicated some problems; and Level 3: indicated extreme problems. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.

    Time frame: Study GS-US-312-0116 or GS-US-312-0117 Baseline; Weeks 24 and 48

07

Results

Posted Aug 20, 2019

Participant flow

Participants were enrolled at study sites in the United States and Europe. The first participant was screened on 03 October 2012. The last study visit occurred on 29 June 2018.

Study GS-US-312-0116
Participant flow — Study GS-US-312-0116
MilestoneIDL+R to IDL 150 mgIDL+R (PD) to IDL 300 mgPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Started10644244
Completed8144244
Not completed25000
Withdrew: Adverse event9000
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject12000
Withdrew: Study terminated by sponsor2000
Withdrew: Other1000
Study GS-US-312-0117
Participant flow — Study GS-US-312-0117
MilestoneIDL+R to IDL 150 mgIDL+R (PD) to IDL 300 mgPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Started7144244
Completed3022018
Not completed4122226
Withdrew: Adverse event221912
Withdrew: Physician decision9064
Withdrew: Withdrawal by subject5064
Withdrew: Study terminated by sponsor3005
Withdrew: Other2111

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the interval from the start of study therapy to the earlier of the first documentation of definitive disease progression or death from any cause; definitive disease progression is chronic lymphocytic leukemia (CLL) progression based on standard criteria other than lymphocytosis alone. PFS was analyzed using Kaplan-Meier (KM) estimates.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Progression-Free Survival (PFS)20.3 (17.3 to 26.3)6.9 (4.1 to 10.7)16.2 (8.8 to 26.2)
PrimarySafety: Percentage of Participants With Any Treatment-Emergent Adverse Events (TEAE), ≥ Grade 3 TEAE, Study Drug-Related TEAE, ≥ Grade 3 Study Drug-Related TEAE, Serious TEAE, Study Drug-Related Serious TEAE, and TEAE Leading to Study Drug Discontinuation

The TEAEs were defined as events in a given study period that met one of the following criteria: * Events with onset dates on or after the start of treatment and up to 30 days after the permanent discontinuation of the study treatment. * The continuing adverse events (AEs) diagnosed prior to the start of treatment and worsened in severity grade, or non-serious AEs at baseline which became serious, or AEs resulting in treatment discontinuation after the start of treatment. The severity of AEs was graded by the investigator according to the common terminology criteria for adverse events (CTCAE), Version 4.03, whenever possible. The relationship of an AE to study drug (idelalisib) was assessed using clinical judgment by the investigator, describing the event as either unrelated or related. Events for which the investigator did not record relationship to study drug were considered related to study drug.

Time frame:
First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months) plus 4 weeks
Reported as:
Number · percentage of participants
Safety: Percentage of Participants With Any Treatment-Emergent Adverse Events (TEAE), ≥ Grade 3 TEAE, Study Drug-Related TEAE, ≥ Grade 3 Study Drug-Related TEAE, Serious TEAE, Study Drug-Related Serious TEAE, and TEAE Leading to Study Drug Discontinuation
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Any TEAE98.2100.097.7
≥ Grade 3 TEAE90.988.190.9
Study Drug-Related TEAE68.259.572.7
≥ Grade 3 Study Drug-Related TEAE47.345.245.5
Serious TEAE80.981.072.7
Study Drug-Related Serious TEAE35.526.229.5
TEAE Leading to Study Drug Discontinuation47.364.350.0
SecondaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). The determination of CLL response and progression were based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs. CR and PR are defined in Protocol Amendment 9, Sections 7.5.1 and 7.5.2.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Overall Response Rate (ORR)85.5 (77.5 to 91.5)47.6 (32.0 to 63.6)68.2 (52.4 to 81.4)
SecondaryLymph Node Response Rate

Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Lymph Node Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Lymph Node Response Rate97.2 (92.0 to 99.4)77.8 (60.8 to 89.9)83.7 (69.3 to 93.2)
SecondaryComplete Response (CR) Rate

CR rate was defined as the percentage of participants who achieved a CR (full definition in Protocol Amendment 9, Section 7.5.1). The determination of CLL response and progression were based on standardized IWCLL criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Complete Response (CR) Rate0.90.00.0
SecondaryTime to Response (TTR)

TTR was defined as the time interval from start of study therapy to the first documentation of CR or PR.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Median · months
Time to Response (TTR)
monthsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Time to Response (TTR)2.1 (1.9 to 3.8)3.6 (1.9 to 4.0)2.8 (1.9 to 4.2)
SecondaryDuration of Response (DOR)

DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause. DOR was analyzed using KM estimates.

Time frame:
From first documentation of CR or PR to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Duration of Response (DOR)21.4 (16.6 to 26.1)11.0 (3.3 to NA)17.6 (13.2 to 37.7)
SecondaryBest Percent Change in Lymph Node Area

The best percent change from baseline in lymph node area (SPD) was defined as the largest decrease in tumor size during the study. The baseline SPD was the last value prior to the baseline reference date. For the participants who only had increases in tumor size from baseline, the smallest increase was considered as the best change from baseline in SPD.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Median · percent change
Best Percent Change in Lymph Node Area
percent changeIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Best Percent Change in Lymph Node Area-80.1 (-86.1 to -70.5)-69.7 (-79.5 to -53.7)-71.4 (-80.4 to -62.7)
SecondarySplenomegaly Response Rate

Splenomegaly response rate was defined as the percentage of participants with baseline splenomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the enlargement of the splenic longest vertical dimension (LVD) (by imaging).

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Splenomegaly Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Splenomegaly Response Rate80.3 (69.5 to 88.5)47.8 (26.8 to 69.4)66.7 (44.7 to 84.4)
SecondaryHepatomegaly Response Rate

Hepatomegaly response rate was defined as the percentage of participants with baseline hepatomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the hepatic LVD (by imaging).

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Hepatomegaly Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Hepatomegaly Response Rate63.0 (48.7 to 75.7)36.4 (17.2 to 59.3)30.0 (11.9 to 54.3)
SecondaryAbsolute Lymphocyte Count (ALC) Response Rate

ALC response rate was defined as the percentage of participants with baseline lymphocytosis (ALC ≥ 4 x 10\^9 cells/L) who achieved an on-study ALC \< 4 x 10\^9 cells/L or demonstrated a ≥ 50% decrease in ALC from baseline; ALC values within 4 weeks post-baseline were excluded from the ALC response rate evaluation.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Absolute Lymphocyte Count (ALC) Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Absolute Lymphocyte Count (ALC) Response Rate94.3 (87.2 to 98.1)66.7 (46.0 to 83.5)64.7 (46.5 to 80.3)
SecondaryPlatelet Response Rate

Platelet response rate was defined as the percentage of participants with baseline thrombocytopenia (platelet count \< 100 x 10\^9/L) who achieved an on-study platelet count ≥ 100 x 10\^9/L or demonstrated a ≥ 50% increase in platelet count from baseline; platelet values within 4 weeks post-baseline or after 8 days post transfusion were excluded from the platelet response rate evaluation.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Platelet Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Platelet Response Rate98.0 (89.4 to 99.9)73.9 (51.6 to 89.8)100.0 (69.2 to 100.0)
SecondaryHemoglobin Response Rate

Hemoglobin response rate was defined as the percentage of participants with baseline anemia (hemoglobin \< 110 g/L \[11.0 g/dL\]) who achieved an on-study hemoglobin ≥ 110 g/L (11.0 g/dL) or demonstrated a ≥ 50% increase in hemoglobin from baseline; hemoglobin values within 4 weeks post-baseline or after 4 weeks of receiving packed cell/whole blood transfusion or after 6 weeks of receiving exogenous growth factors (eg, darbepoetin alfa) were excluded from the hemoglobin response evaluation.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Hemoglobin Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Hemoglobin Response Rate83.1 (71.0 to 91.6)45.8 (25.6 to 67.2)81.8 (48.2 to 97.7)
SecondaryNeutrophil Response Rate

Neutrophil response rate was defined as the percentage of participants with baseline neutropenia (absolute neutrophil count \[ANC\] ≤ 1.5 x 10\^9/L) who achieved an ANC \> 1.5 x 10\^9/L or demonstrated a ≥ 50% increase in ANC from baseline; ANC values within 4 weeks of post-baseline or after 2 weeks of receiving exogenous growth factors (eg, filgrastim, granulocyte-colony stimulating factor \[G-CSF\], lenograstim) or after 4 weeks of receiving Neulasta® were excluded from response evaluation.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Number · percentage of participants
Neutrophil Response Rate
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Neutrophil Response Rate96.3 (81.0 to 99.9)90.9 (58.7 to 99.8)100.0 (54.1 to 100.0)
SecondaryOverall Survival

Overall survival was defined as the time interval from start of study therapy to death from any cause. Overall survival was analyzed using KM estimates. Data presented includes all available survival information from Study GS-US-312-0116 (including data in long-term follow-up) and Study GS-US-312-0117 (including any data in long-term follow-up) up to the database finalization dates. Data from surviving participants were censored at the last time that the participant was known to be alive on study or long-term follow-up. Data presented includes all participants who were randomized to Study GS-US-312-0116 regardless if they entered Study GS-US-312-0117 or not.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Median · months
Overall Survival
monthsIDL+RPlacebo+R
Overall Survival40.6 (28.5 to 57.3)34.6 (16.0 to NA)
SecondaryBest Change From Baseline in Health-Related Quality of Life (HRQL) Domain and Symptom Scores Based on the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire

The FACT-Leu questionnaire included subscales for physical well-being (PWB, 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB, 6 items), functional well-being (FWB, 7 items), and additional concerns or Leukemia-Specific Subscale (LeuS, 17 items). The FACT-Leu scoring guide identified those negatively stated items that must have been reversed before being added to obtain subscale totals. Negatively stated items were reversed by subtracting the response from "4". After reversing proper items, all subscale items were summed to get total subscale scores with the range of 0-28, 0-28, 0-24, 0-28, 0-68 for PWB, SWB, EWB, FWB, and LeuS, respectively. FACT-Leu total score ranged from 0 to 176. Higher scores indicated a better quality of life. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.

Time frame:
Study GS-US-312-0116 or GS-US-312-0117 Baseline up to Week 184
Reported as:
Mean · units on a scale
Best Change From Baseline in Health-Related Quality of Life (HRQL) Domain and Symptom Scores Based on the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire
units on a scaleIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Total Score: Baseline128.4 ± 22.72116.7 ± 29.56128.1 ± 29.16
PWB: Baseline22.8 ± 4.4220.2 ± 5.9321.9 ± 5.41
SWB: Baseline22.5 ± 5.5322.5 ± 5.0623.5 ± 5.04
EWB: Baseline19.1 ± 3.4417.3 ± 4.9717.6 ± 4.48
FWB: Baseline18.0 ± 6.5715.0 ± 7.1718.0 ± 6.88
LeuS: Baseline46.0 ± 10.6441.7 ± 12.7447.0 ± 12.01
Total Score: Best Change from Baseline21.8 ± 19.6420.2 ± 19.9114.9 ± 12.04
PWB: Best Change from Baseline3.1 ± 4.653.6 ± 4.263.4 ± 3.81
SWB: Best Change from Baseline2.9 ± 5.212.0 ± 2.882.1 ± 2.39
EWB: Best Change from Baseline3.1 ± 2.753.1 ± 3.682.8 ± 3.14
FWB: Best Change from Baseline5.1 ± 5.804.1 ± 5.013.1 ± 2.94
LeuS: Best Change from Baseline11.3 ± 9.1310.1 ± 8.787.8 ± 5.59
SecondaryBest Change From Baseline in Karnofsky Performance Status (KPS)

KPS is a tool used to measure the ability to perform ordinary tasks. The score ranges from 0 to 100, with a higher score indicating that the participant is better able to carry out daily activities. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.

Time frame:
Study GS-US-312-0116 or GS-US-312-0117 Baseline up to Week 190
Reported as:
Mean · units on a scale
Best Change From Baseline in Karnofsky Performance Status (KPS)
units on a scaleIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Baseline80.7 ± 12.4778.1 ± 14.1886.8 ± 8.83
Best Change From Baseline11.1 ± 10.317.1 ± 8.674.3 ± 6.98
SecondaryChanges From Baseline in Phosphatidylinositol 3-kinase (PI3Kδ)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway Activation as a Measure of PI3Kδ Pathway Activity
Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)

No measurements were reported for this outcome.

SecondaryOverall Change From Baseline in the Plasma Concentrations of Disease-Associated Chemokines and Cytokines

The percent of average on-treatment biomarker concentration of baseline (%Baseline) was used to evaluate the overall pharmacodynamics change on the biomarkers with IDL treatment. The average on-treatment biomarker concentration is calculated using area under curve (AUC) following the trapezoidal rule. The biomarkers with median AUC value of 100 indicated no overall on-treatment biomarker changes compared to the baseline. The biomarkers with median AUC value greater than 100 or less than 100 indicated an increase or decrease, respectively, on-treatment biomarker changes from the baseline.

Time frame:
GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Reported as:
Median · percentage of baseline
Overall Change From Baseline in the Plasma Concentrations of Disease-Associated Chemokines and Cytokines
percentage of baselineIDL/Placebo+R to IDL
Tumor Necrosis Factor (TNF)-alpha36.73 (5.34 to 183.56)
Macrophage Inflammatory Protein (MIP)1-alpha26.55 (3.76 to 236.22)
Interleukin (IL)-1058.65 (2.36 to 1706.34)
IL-15111.18 (51.28 to 230.1)
IL-12p4064.89 (11.3 to 2012.31)
RANTES (CCL5)131.94 (6.76 to 3715.99)
IL-1ra114.22 (11.64 to 608.17)
Interferon (IFN)-gamma127.72 (10.55 to 4736.96)
C-Reactive Protein (CRP)132.38 (9.67 to 7625.53)
IFN-gamma-induced protein (IP)-10 (CXCL10)88.5 (15.24 to 786.21)
IL-791.82 (14.47 to 960.7)
Granulocyte-colony stimulating factor (G-CSF)96.59 (3.83 to 1586.48)
IL-17A100 (8.8 to 1311.69)
IL-6100 (7.13 to 2817.44)
IL-8102.59 (2.47 to 1724.25)
SecondaryStudy Drug Compliance as Assessed by the Percentage of Participants Adhering to Treatment

Adherence percentage was calculated as the sum of tablets dispensed - the sum of tablets returned divided by the sum of the overall dosing period (total daily tablets x dosing duration), taking into account investigator-prescribed interruptions.

Time frame:
First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months)
Reported as:
Number · percentage of participants
Study Drug Compliance as Assessed by the Percentage of Participants Adhering to Treatment
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Adherence ≥ 75%100.097.6100.0
Adherence < 75%0.02.40.0
SecondaryPlasma Trough (Predose) and Peak (1.5 Hours Postdose) Concentrations of Idelalisib
Time frame:
Weeks 4, 12, and 24
Reported as:
Median · ng/mL
Plasma Trough (Predose) and Peak (1.5 Hours Postdose) Concentrations of Idelalisib
ng/mLIDL+R to IDL 150 mgIDL+R (PD) to IDL 300 mgPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Week 4: Predose384.0 (166.5 to 681.5)470.0 (317.0 to 631.0)301.5 (195.0 to 494.0)412.0 (211.0 to 646.0)
Week 4: 1.5 Hours Postdose2115.0 (1370.0 to 2750.0)3940.0 (1550.0 to 4000.0)2580.0 (1880.0 to 3080.0)1720.0 (1200.0 to 2660.0)
Week 12: Predose370.0 (196.0 to 745.0)570.0 (355.0 to 643.0)335.0 (190.0 to 470.0)298.0 (212.0 to 691.0)
Week 12: 1.5 Hours Postdose2110.0 (1595.0 to 2665.0)3800.0 (3160.0 to 4710.0)2245.0 (1655.0 to 3255.0)1940.0 (1430.0 to 2450.0)
Week 24: Predose307.0 (179.0 to 584.0)637.0 (524.0 to 930.0)362.0 (162.0 to 550.0)350.5 (261.0 to 504.5)
Week 24: 1.5 Hours Postdose2270.0 (1560.0 to 2790.0)5630.0 (5550.0 to 5660.0)2180.0 (1760.0 to 2980.0)2010.0 (1210.0 to 2430.0)
SecondaryChange in Health Status as Assessed Using the EuroQoL Five-Dimension (EQ-5D) Utility Measure

Change in health status was defined as the change from baseline in overall health and single-item dimension scores as assessed using the EQ-5D utility measure. Percentage of participants with different level of problem were reported. Level 1: indicated no problem; Level 2: indicated some problems; and Level 3: indicated extreme problems. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.

Time frame:
Study GS-US-312-0116 or GS-US-312-0117 Baseline; Weeks 24 and 48
Reported as:
Number · percentage of participants
Change in Health Status as Assessed Using the EuroQoL Five-Dimension (EQ-5D) Utility Measure
percentage of participantsIDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
Baseline: Anxiety/Depression, Level 170.450.056.8
Baseline: Anxiety/Depression, Level 228.742.943.2
Baseline: Anxiety/Depression, Level 30.97.10.0
Baseline: Mobility, Level 160.238.161.4
Baseline: Mobility, Level 239.859.538.6
Baseline: Mobility, Level 30.02.40.0
Baseline: Pain/Discomfort, Level 153.350.045.5
Baseline: Pain/Discomfort, Level 239.345.250.0
Baseline: Pain/Discomfort, Level 37.54.84.5
Baseline: Self-Care, Level 190.776.284.1
Baseline: Self-Care, Level 29.319.015.9
Baseline: Self-Care, Level 30.04.80.0
Baseline: Usual Activities, Level 156.528.652.3
Baseline: Usual Activities, Level 236.152.445.5
Baseline: Usual Activities, Level 37.419.02.3
Week 24: Anxiety/Depression, Level 183.165.069.6
Week 24: Anxiety/Depression, Level 215.635.030.4
Week 24: Anxiety/Depression, Level 31.30.00.0
Week 24: Mobility, Level 170.165.069.6
Week 24: Mobility, Level 229.935.030.4
Week 24: Mobility, Level 30.00.00.0
Week 24: Pain/Discomfort, Level 162.365.043.5
Week 24: Pain/Discomfort, Level 235.130.047.8
Week 24: Pain/Discomfort, Level 32.65.08.7
Week 24: Self-Care, Level 192.285.091.3
Week 24: Self-Care, Level 26.515.08.7
Week 24: Self-Care, Level 31.30.00.0
Week 24: Usual Activities, Level 168.475.060.9
Week 24: Usual Activities, Level 228.925.034.8
Week 24: Usual Activities, Level 32.60.04.3
Week 48: Anxiety/Depression, Level 184.190.050.0
Week 48: Anxiety/Depression, Level 215.910.050.0
Week 48: Anxiety/Depression, Level 30.00.00.0
Week 48: Mobility, Level 172.760.066.7
Week 48: Mobility, Level 227.340.033.3
Week 48: Mobility, Level 30.00.00.0
Week 48: Pain/Discomfort, Level 156.860.050.0
Week 48: Pain/Discomfort, Level 243.230.050.0
Week 48: Pain/Discomfort, Level 30.010.00.0
Week 48: Self-Care, Level 195.590.083.3
Week 48: Self-Care, Level 24.50.016.7
Week 48: Self-Care, Level 30.010.00.0
Week 48: Usual Activities, Level 172.770.050.0
Week 48: Usual Activities, Level 225.020.033.3
Week 48: Usual Activities, Level 32.310.016.7

Adverse events

Collected over Adverse Events: First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months) plus 30 days; All-Cause Mortality: First IDL dose date up to 67.6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDL+R to IDL 150 mg37/71 (52.1%)54/71 (76.1%)70/71 (98.6%)
IDL+R (PD) to IDL 300 mg3/4 (75%)2/4 (50%)4/4 (100%)
Placebo+R (PD) to IDL 150 mg25/42 (59.5%)34/42 (81%)41/42 (97.6%)
Placebo+R to IDL 150 mg16/44 (36.4%)32/44 (72.7%)43/44 (97.7%)
Most frequent serious events
Showing 10 of 156
Most frequent serious events
EventIDL+R to IDL 150 mgIDL+R (PD) to IDL 300 mgPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
PneumoniaInfections and infestations6/712/410/423/44
Sepsis pasteurellaInfections and infestations0/711/40/420/44
HypoxiaRespiratory, thoracic and mediastinal disorders1/711/40/420/44
Aortic aneurysmVascular disorders0/711/40/420/44
HypotensionVascular disorders0/711/40/421/44
DiarrhoeaGastrointestinal disorders7/710/44/428/44
Febrile neutropeniaBlood and lymphatic system disorders4/710/45/421/44
PyrexiaGeneral disorders4/710/41/424/44
CellulitisInfections and infestations4/710/40/424/44
ColitisGastrointestinal disorders5/710/41/423/44
Most frequent other events
Showing 10 of 100
Most frequent other events
EventIDL+R to IDL 150 mgIDL+R (PD) to IDL 300 mgPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mg
DiarrhoeaGastrointestinal disorders30/712/417/4226/44
AnaemiaBlood and lymphatic system disorders8/712/45/424/44
ThrombocytopeniaBlood and lymphatic system disorders5/712/43/424/44
FatigueGeneral disorders15/712/413/429/44
PyrexiaGeneral disorders17/710/412/4216/44
CoughRespiratory, thoracic and mediastinal disorders21/710/412/4216/44
NauseaGastrointestinal disorders11/710/412/4212/44
NeutropeniaBlood and lymphatic system disorders14/711/49/426/44
Abdominal distensionGastrointestinal disorders3/711/40/421/44
Abdominal painGastrointestinal disorders8/711/45/425/44

Baseline characteristics

Full Analysis Set included participants in the Intent-to-Treat (ITT) Analysis Set (all participants randomized in Study GS-US-312-0116) who received ≥ 1 dose of IDL, with treatment assignments designated according to randomization in Study GS-US-312-0116. Baseline data presented were collected at the beginning of Study GS-US-312-0116.

Age, Customized
Age, Customized(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
< 65 years21131044
≥ 65 years892934152
Sex: Female, Male
Sex: Female, Male(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
Female34111863
Male763126133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
Ethnicity — Hispanic or Latino3115
Ethnicity — Not Hispanic or Latino1013942182
Ethnicity — Not Permitted6219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
Race — White1003740177
Race — Black or African American3036
Race — Native Hawaiian or Other Pacific Islander0000
Race — Asian0000
Race — American Indian or Alaska Native0000
Race — Other2204
Race — Not Permitted5319
Region of Enrollment
Region of Enrollment(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
United States803830148
United Kingdom183627
Italy2147
France3014
Germany70310
17p Deletion and/or TP53 Mutation Status
17p Deletion and/or TP53 Mutation Status(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
Either46211481
Neither642130115
Immunoglobulin heavy chain variable region (IgHV) Mutation Status
Immunoglobulin heavy chain variable region (IgHV) Mutation Status(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
Mutated196732
Unmutated913637164
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(Participants)IDL+R to IDLPlacebo+R (PD) to IDL 150 mgPlacebo+R to IDL 150 mgTotal
KPS = 401001
KPS = 503104
KPS = 606208
KPS = 70204428
KPS = 8042192081
KPS = 9023121247
KPS = 100154827
08

Study locations

45 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • University of California, San Diego - Moores Cancer Center
    La Jolla, California 92093, United States
  • Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • UCLA
    Santa Monica, California 90404, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Rocky Mountain Blood and Marrow Transplant Program
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Georgetown University Medical Center Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Collaborative Research Group
    Boynton Beach, Florida 33435, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11042, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Willamette Valley Cancer Center
    Springfield, Oregon 97477, United States
  • Northwest Cancer Specialists, PC
    Tualatin, Oregon 97062, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Cancer Care Network of South Texas
    San Antonio, Texas 78217, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc.
    Roanoke, Virginia 24014, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1024, United States
  • Yakima Valley Memorial Hospital/North Star Lodge
    Yakima, Washington 98902, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Hämatologische und Internistische Gemeinschaftspraxis Dres. Eckart / Häcker
    Erlangen, 91052, Germany
  • Universitätsklinikum Köln
    Köln, 50937, Germany
  • Ospedale San Raffaele S.r.l.
    Milano, 20132, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Dorset County Hospital
    Dorchester, DT1 2JY, United Kingdom
  • Northwick Park Hospital
    Harrow, HA1 3UJ, United Kingdom
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • Hammersmith Hospital
    London, W12 0NN, United Kingdom
  • Princess Royal University Hospital
    Orpington, BR6 8ND, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Coutre SE, Furman RR, Sharman, JP, Cheson BD, Pagel JM, Hillmen P, et al. Second Interim Analysis of a Phase 3 Study of Idelalisib (Zydelig®) Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia: Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood 2014; 124 (21):330
  • Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Efficacy of Idelalisib in CLL Subpopulations Harboring Del(17p) and Other Adverse Prognostic Factors: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Trial [Poster 7011]. American Society of Clinical Oncology (ASCO) 50th Annual Meeting; 2014 May 30-June 3; Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 7011)
  • Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17. PubMed 30995176 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in May 2018, 67 months.

Results were first posted in Aug 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2012
First posted
Feb 27, 2012
StartActual
Oct 3, 2012
Primary completionActual
May 21, 2018
CompletionActual
Jun 29, 2018
Results first posted
Aug 20, 2019
Last update
Aug 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01539291
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 27, 2012
Start date
Oct 3, 2012
Primary completion
May 21, 2018
Completion
Jun 29, 2018
Results posted
Aug 20, 2019
Last update
Aug 20, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion